Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clesitamig - Chugai Pharmaceutical

Next Previous
Drug Profile

Clesitamig - Chugai Pharmaceutical

Alternative Names: ALPS-12; RG-6524; RO-7616789

Latest Information Update: 15 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Class Antineoplastics; Fab fragments; Immunotherapies; Recombinant fusion proteins; Trispecific antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Neuroendocrine tumours; Small cell lung cancer; Solid tumours

Most Recent Events

  • 15 Oct 2025 Clesitamig is still in phase I trial for Solid tumours (IV) at an unknown location
  • 01 Sep 2025 Chugai Pharmaceutical plans a phase I trial for Small cell lung cancer (Recurrent, Second-line therapy or greater) in Japan (IV, Infusion) (NCT07107490)
  • 04 Mar 2025 Roche completes a phase I trial in Neuroendocrine tumours and Small cell lung cancer (Late-stage disease, Second-line therapy or greater) in USA, Poland, Spain, Denmark, Japan (IV) (NCT05619744)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top